Concordance of three automated procalcitonin immunoassays at medical decision points

Hae Weon Cho, Sun Hee Kim, Yonggeun Cho, Seok Hoon Jeong, Sang Guk Lee

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Procalcitonin (PCT) is a useful bacterial infection biomarker with the potential for guiding antibiotic therapy. We evaluated the concordance of three automated PCT immunoassays: Kryptor (BRAHMS GmbH, Hennigsdorf, Germany), Atellica IM 1600 (Siemens Healthcare Diagnostics, Munich, Germany), and Cobas e801 (Roche Diagnostics, Mannheim, Germany). In 119 serum samples with a PCT concentration <5.00 μg/L, Kryptor (reference assay) was compared with the other two immunoassays by Spearman’s rank correlation, regression analysis, and concordance at two antibiotic stewardship medical decision points: 0.25 and 0.50 μg/L. The Atellica IM 1600 and Cobas e801 results showed high correlations with those of Kryptor, with correlation coefficient (ρ) values of 0.97 and 0.99, respectively. However, negative biases were observed in both immunoassays (slope/y-intercept: 0.75/–0.00 for Atellica IM 1600; 0.88/–0.01 for Cobas e801). Atellica IM 1600 and Cobas e801 demonstrated excellent concordance with Kryptor at both medical decision points, with linearly weighted κ values of 0.90 and 0.92, respectively, despite discrepancies, which were more prominent at the 0.25 μg/L medical decision point. Based on these biases and discrepancies, the alternate use of different PCT immunoassays in repeat examinations is inadvisable. Standardization is required before comparing the results of different PCT immunoassays.

Original languageEnglish
Pages (from-to)419-423
Number of pages5
JournalAnnals of laboratory medicine
Issue number4
Publication statusPublished - 2021 Jul 1

Bibliographical note

Publisher Copyright:
© Korean Society for Laboratory Medicine.

All Science Journal Classification (ASJC) codes

  • Biochemistry, medical
  • Clinical Biochemistry


Dive into the research topics of 'Concordance of three automated procalcitonin immunoassays at medical decision points'. Together they form a unique fingerprint.

Cite this